Peptide LibraryHuman study PLS-00211
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteersregistry entry · NCT00743769 (WITHDRAWN, no results posted, planned enrollment 0)
Design and participants
- Design
- Other design
- Population
- Healthy volunteers (planned); the registered conditions of interest are myocardial infarction and ischemia
- Conditions
- Myocardial Infarction, Myocardial Ischemia
- Planned enrollment (registry)
- 0
- Enrolled
- 0
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- other: The study was withdrawn with zero actual enrollment and no results, so it provides no data on any outcome.
- inappropriate population: The planned population was healthy volunteers, which is unlike patients with the claim conditions (e.g., dry eye).
- small or imprecise: The study was withdrawn with 0 participants enrolled, so no data were generated.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
- Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”
Where each value comes from
- arms: NCT NCT00743769, registry (interventions field) · extracted by AI (automated, not verified by a person)
- design: NCT NCT00743769, registry (phases, study_type, status fields) · extracted by AI (automated, not verified by a person)
- limitations: NCT NCT00743769, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
- participants: NCT NCT00743769, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
- population: NCT NCT00743769, title (title) · extracted by AI (automated, not verified by a person)
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).